AwesomeCapital
Search This Blog
Saturday, March 28, 2026
Galderma Announces Late-Breaking Nemolizumab Data
AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis
https://www.galderma.com/news/aad-2026-late-breaking-data-atopic-dermatitis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.